| Not Yet Recruiting | A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Tar NCT07416032 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Recruiting | A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) NCT07294365 | Dizal Pharmaceuticals | Phase 2 |
| Not Yet Recruiting | National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent NCT07268898 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Recruiting | A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia NCT07175493 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | An Exploratory Study of Golidocitinib in Adult Patients With ITP NCT07196163 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thro NCT07194850 | argenx | Phase 2 / Phase 3 |
| Recruiting | Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia NCT07095127 | Nuvig Therapeutics, Inc. | Phase 2 |
| Recruiting | An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmun NCT07174843 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immun NCT07065968 | Peking University People's Hospital | Phase 2 |
| Recruiting | Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia NCT06973356 | Anhui Provincial Hospital | N/A |
| Not Yet Recruiting | Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia NCT07046013 | Sohag University | — |
| Recruiting | A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia NCT06721013 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Recruiting | V-IMMUNE® for Immune Thrombocytopenia NCT06962631 | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | Phase 3 |
| Not Yet Recruiting | Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke NCT07070193 | Peking University People's Hospital | — |
| Not Yet Recruiting | Longitudinal Observational Study on Immune Thrombocytopenia NCT07068425 | Peking University People's Hospital | — |
| Not Yet Recruiting | Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP NCT07057778 | Peking University People's Hospital | Phase 2 |
| Recruiting | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) NCT07043946 | Climb Bio, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia NCT06853444 | Shanghai Escugen Biotechnology Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus NCT06943937 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia NCT06799611 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Enrolling By Invitation | Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) NCT06723106 | Chugai Pharmaceutical | Phase 1 |
| Recruiting | Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) NCT06371417 | Chugai Pharmaceutical | Phase 1 |
| Recruiting | IgIV Plus Prednisone vs High-dose Dexamethasone for ITP NCT04968899 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Terminated | Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disord NCT05086744 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies NCT04915482 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 / Phase 3 |
| Unknown | Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) NCT03975361 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) NCT04669600 | Bioverativ, a Sanofi company | Phase 2 |
| Completed | A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Pa NCT04346654 | Novartis Pharmaceuticals | Phase 2 |
| Completed | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Pat NCT03951623 | Hutchison Medipharma Limited | Phase 1 |
| Completed | Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia ( NCT02868060 | Kyowa Kirin China Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With NCT01054443 | Shionogi | Phase 2 |
| Completed | Rituximab as Second Line Treatment for ITP NCT00344149 | Ostfold Hospital Trust | Phase 3 |
| Completed | Autoantibody Specificity and Response to IVIG in ITP NCT01666795 | Shandong University | — |